
Opinion|Videos|March 12, 2024
KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L
An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
4
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
5







































